SCHEMBL15411159

SCHEMBL15411159

Cc1c(-c2ccnn2-c2ccc(C#N)cc2)cn2nc(NC(=O)CCCBr)nc2c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ELANE P08246 6/20 0.45
SLC5A1 P13866 9/20 0.37
ADORA2A P29274 1/20 0.35
MALT1 Q9UDY8 1/20 0.35
CETP P11597 1/20 0.34
JAK2 O60674 1/20 0.33
KCNK3 O14649 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15412588 0.94 ELANE (0.45) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15425389 0.93 ELANE (0.44) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15411585 0.93 ELANE (0.46) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15411725 0.93 ELANE (0.46) ELANESLC5A1ADORA2AMALT1CETP
Bromide SCHEMBL15411633 0.92 ELANE (0.44) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15412357 0.92 ELANE (0.44) ELANESLC5A1ADORA2AMALT1
SCHEMBL15411098 0.92 ELANE (0.46) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15411530 0.92 ELANE (0.45) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15412243 0.91 ELANE (0.47) ELANESLC5A1ADORA2AMALT1CETP
SCHEMBL15410997 0.91 ELANE (0.45) ELANESLC5A1ADORA2AMALT1CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 EP disclosed
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 EP disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
EP-2872509-A1 INHIBITION OF ENZYMES Chiesi Farmaceutici S.p.A. (IT) 2015-05-20 EP disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
WO-2014009425-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A. (IT) 2014-01-16 WO disclosed
WO-2014009425-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A. (IT) 2014-01-16 WO disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018345-A1 INHIBITION OF ENZYMES SERPINB1, ELANE, MPO ELANE 2/4885SLC5A1 2125/4885ADORA2A 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.